stoxline Quote Chart Rank Option Currency Glossary
  
AnaptysBio, Inc. (ANAB)
23.17  -0.22 (-0.94%)    06-20 16:00
Open: 23.42
High: 23.42
Volume: 389,483
  
Pre. Close: 23.39
Low: 22.505
Market Cap: 681(M)
Technical analysis
2025-06-20 4:38:26 PM
Short term     
Mid term     
Targets 6-month :  28.82 1-year :  33.66
Resists First :  24.68 Second :  28.82
Pivot price 23.03
Supports First :  21.19 Second :  19.04
MAs MA(5) :  23.52 MA(20) :  22.51
MA(100) :  19.14 MA(250) :  24.17
MACD MACD :  0.8 Signal :  0.8
%K %D K(14,3) :  78.3 D(3) :  81.1
RSI RSI(14): 56
52-week High :  41.3 Low :  12.21
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ ANAB ] has closed below upper band by 46.2%. Bollinger Bands are 24.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 23.45 - 23.64 23.64 - 23.76
Low: 22.11 - 22.32 22.32 - 22.46
Close: 22.89 - 23.22 23.22 - 23.44
Company Description

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Headline News

Thu, 19 Jun 2025
AnaptysBio, Inc. (NASDAQ:ANAB) Shares Sold by Assenagon Asset Management S.A. - MarketBeat

Wed, 18 Jun 2025
AnaptysBio, Inc. (NASDAQ:ANAB) Holdings Trimmed by Bank of America Corp DE - MarketBeat

Fri, 06 Jun 2025
AnaptysBio: Positive RA Data Bodes Well For Continued Rosnilimab Advancement (NASDAQ:ANAB) - Seeking Alpha

Wed, 04 Jun 2025
HC Wainwright & Co. Upgrades AnaptysBio (ANAB) - Nasdaq

Wed, 28 May 2025
AnaptysBio (ANAB) Maintains Buy Rating with Raised Price Target | ANAB Stock News - GuruFocus

Tue, 27 May 2025
New PD-1 Drug Trial Data: Rosnilimab Shows Promise for Rheumatoid Arthritis Treatment - Key Results Coming - Stock Titan

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 29 (M)
Shares Float 18 (M)
Held by Insiders 5 (%)
Held by Institutions 134.1 (%)
Shares Short 8,830 (K)
Shares Short P.Month 10,770 (K)
Stock Financials
EPS -4.77
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.12
Profit Margin -125.7 %
Operating Margin -99.2 %
Return on Assets (ttm) -15.2 %
Return on Equity (ttm) -343.9 %
Qtrly Rev. Growth 286.7 %
Gross Profit (p.s.) -1.91
Sales Per Share 3.8
EBITDA (p.s.) -3.4
Qtrly Earnings Growth 0 %
Operating Cash Flow -109 (M)
Levered Free Cash Flow -60 (M)
Stock Valuations
PE Ratio -4.87
PEG Ratio 0
Price to Book value 20.68
Price to Sales 6.08
Price to Cash Flow -6.26
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android